Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. - Gottlieb,A.B.; Masud,S.; Ramamurthi,R.; Abdulghani,A.; Romano,P.; Chaudhari,U.; Dooley,L.T.; Fasanmade,A.A.; Wagner,C.L. (J Am Acad Dermatol, 2003)